Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GRK6 | P43250 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454074 | 0.88 | GRK6 (0.56) | NPC1RAB9AL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL6449979 | 0.85 | GRK6 (0.51) | NPC1RAB9AL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL6454593 | 0.83 | GRK6 (0.51) | NPC1RAB9ASMN1; SMN2TDP1GRK6 | |
| SCHEMBL6449943 | 0.82 | SMN1; SMN2 (0.61) | NPC1RAB9AL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL6451170 | 0.81 | GRK6 (0.49) | NPC1RAB9AL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL6449701 | 0.81 | GRK6 (0.49) | NPC1RAB9ASMN1; SMN2TDP1PKM | |
| SCHEMBL4599223 | 0.81 | MAPT (0.54) | NPC1RAB9AL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL6449907 | 0.81 | GRK6 (0.48) | NPC1RAB9ASMN1; SMN2TDP1GRK6 | |
| SCHEMBL6452160 | 0.80 | RAB9A (0.62) | NPC1RAB9AL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL6454836 | 0.80 | GRK6 (0.48) | NPC1RAB9ASMN1; SMN2TDP1GRK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | NPC1 59/4885RAB9A 2483/4885L3MBTL1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.